Edwards Lifesciences Corp

EW is in a confirmed Stage 4 decline after breaking key support with a decisive Support Failure pattern. Price remains below declining EMAs and the 50 DMA, and recent bounce into these moving averages was rejected. Following our Stable strategy, we initiate immediate sell-side execution at structural resistance to reduce exposure in the ongoing downtrend.

• ↑Q1 sales $1.65 B (+12.7% YoY) driven by TAVR and TMTT demand
• ↑Raised full-year sales growth guidance to 9–11% on strong global momentum
• ↓Weak earnings yield indicates market may overprice shares